Tandem Diabetes Care Inc
Tandem Diabetes Care Inc (TNDM) Covered Calls
Tandem Diabetes Care Inc trades in the Medical Devices industry with an IV Rank of 68.25%, average versus the past year. TNDM's highest covered call setup is the $22.00 strike expiring Nov 20, 2026, sorted by theoretical annualized return. It's 22.29% out of the money with 15 days to expiration, a 24.51% return until expiration, and a 596.50% theoretical annualized return. Across the setups shown, annualized returns run from 133.48% to 596.50% at strikes between $18.00 and $35.00, with 15 to 197 days to expiration, as of Nov 5, 2026.
Read more
Running TNDM covered calls helps you generate income from Tandem Diabetes Care Inc shares you already own, turning a long stock position into a yield producing asset. A covered call means holding the underlying stock and selling a call option against it, collecting premium in exchange for capping upside at the strike. Use our scanner to find the best TNDM covered calls in real time and filter for the strikes, expiries, and premiums that fit your strategy.
A covered call pairs limited risk with a clear income profile. If TNDM stays below the strike at expiration, you keep the premium and the shares. If it rises above, you deliver the stock at the strike and still pocket the premium. Selling TNDM covered calls works best when implied volatility is elevated, since richer premiums improve the risk reward. Key inputs include strike selection relative to delta, days to expiration, annualized return, and probability of assignment, all of which determine whether a given TNDM covered call is worth writing.
Tandem Diabetes Care, Inc., a medical device company, designs, develops, and commercializes various products for people with insulin-dependent diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform that comprises t:slim X2 pump, its 300-unit disposable insulin cartridge, and an infusion set. It also provides t:slim X2 insulin with Basal-IQ and control IQ technology; t:slim X2 with G5 Integration; and Tandem Device Updater, a tool that allows users to update their pump's software. In addition, the company offers t:connect, a web-based data management application, which provides a visual way to display diabetes therapy management data from the pump, continuous glucose monitoring, and supported blood glucose meters for users, their caregivers, and their healthcare providers; and Sugarmate, a mobile app for people with diabetes who use insulin.
| 2026-11-20 | 15 | 22.00 | 22.29 | 0.40 | 1.95 | 441.00 | 24.51 | 596.50 | -2.22 | +0.34 | 77 | 1.55 |
| 2027-02-19 | 106 | 35.00 | 94.55 | 0.05 | 1.35 | 1706.00 | 94.83 | 326.54 | -0.28 | +0.17 | 8 | 1.30 |
| 2026-11-20 | 15 | 19.00 | 5.61 | 0.95 | 1.70 | 196.00 | 10.89 | 265.11 | -5.28 | +0.46 | 914 | 0.75 |
| 2027-02-19 | 106 | 30.00 | 66.76 | 0.10 | 1.15 | 1211.00 | 67.32 | 231.79 | -0.56 | +0.18 | 58 | 1.05 |
| 2027-01-15 | 71 | 25.00 | 38.97 | 0.05 | 3.00 | 706.00 | 39.24 | 201.75 | -0.28 | +0.34 | 167 | 2.95 |
| 2026-12-18 | 43 | 22.00 | 22.29 | 0.20 | 2.80 | 421.00 | 23.40 | 198.64 | -1.11 | +0.38 | 10 | 2.60 |
| 2026-12-18 | 43 | 21.00 | 16.73 | 0.40 | 3.20 | 341.00 | 18.95 | 160.90 | -2.22 | +0.43 | 0 | 2.80 |
| 2027-02-19 | 106 | 25.00 | 38.97 | 0.85 | 2.85 | 786.00 | 43.69 | 150.45 | -4.72 | +0.37 | 7 | 2.00 |
| 2026-11-20 | 15 | 18.00 | 0.06 | 1.05 | 3.20 | 106.00 | 5.89 | 143.38 | -5.84 | +0.56 | 198 | 2.15 |
| 2027-05-21 | 197 | 30.00 | 66.76 | 0.95 | 2.00 | 1296.00 | 72.04 | 133.48 | -5.28 | +0.29 | 180 | 1.05 |
As of Nov 5, 2026
Prices move. This one stays.Lock in 5 years at a special price and save $2,243. Ending soon.See the Early Bird Black Friday deal →Stock Statistics
- IndustryMedical Devices
- SectorHealthcare
- IV Rank68.25% Moderate
- Market cap (M$)1,268
- 52 weeks high-38.72%
- 52 weeks low48.21%
- Analyst recommendationBuy
2.00 - Target price$27.75
52.72% above the current stock price - Dividend—
- Payout ratio—
- Earnings date2026-11-05
- P/E—
- Future P/E491.75
- EPS (ttm)-0.72
- EPS growth next 5 years—
As of Nov 6, 2026